







Peripheral blood count is one of the most accessible, 
cost-effective, and frequently performed diagnostic 
tests in medical practice. Both venous whole blood 
sampling and subsequent laboratory analysis are 
technically simple, allowing the results to be obtained 
very quickly. Abnormal results may direct further dif-
ferential diagnosis.
The measured parameters include the following: 
red blood cells (RBC), haemoglobin (HGB), white 
blood cells (WBC), platelets (PLT), and haematocrit 
(HCT). Both manual and automatic blood smears en-
able quantitative and qualitative assessment of blood 
cells subpopulations. For leukocytes the proportion 
of each type in the total pool of white blood cells 
is determined. The types are as follows: granulo-
cytes — neutrophils, eosinophils and basophils, and 
agranulocytes: lymphocytes and monocytes. We also 
receive information on red blood cells parameters 
— mean corpuscular haemoglobin (MCH), mean 
corpuscular haemoglobin concentration (MCHC), 
mean corpuscular volume (MCV) and detailed 
platelets parameters including MPV — mean platelet 
volume, PDW — platelet distribution width, which is 
a platelet volume variability index, PCT — plateletcrit, 
and P-LCR — platelet large cell ratio, describing the 
percentage of large platelets in the total number of 
thrombocytes.
The hormonal status may influence the parameters 
assessed in the blood count, thus their changes may 
reflect endocrine diseases. The aim of this study is to 
summarise current literature on blood count changes 
that should prompt diagnosis towards endocrine 




In countries well supplied with iodine, the most com-
mon cause of hypothyroidism is chronic autoimmune 
thyroiditis (Hashimoto’s disease), which is included 
in a wider group of autoimmune thyroid diseases 
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observed, but it is proportionally less pronounced 
than the increase in the volume of plasma. The 
physiological anaemia in pregnant women improves 
haemodynamic circulation in the course of increased 
resistance of blood vessels and increased blood flow 
through uteroplacental vessels occurring during 
pregnancy, which provides a better blood supply. 
Additionally, the level of iron is decreased due to in-
creased utilization and transport to the foetus. On the 
other hand, iron deficiency is often linked to thyroid 
diseases, as less iron reduces the activity of thyroid 
peroxidase — an enzyme essential for the produc-
tion of thyroid hormones. Concluding, in pregnant 
women a complete blood count should be monitored, 
and in case of anaemia, diagnostics directed towards 
thyroid diseases should be initiated, even if they were 
not diagnosed before pregnancy [8].
Keskin et al. described differences in haematologi-
cal parameters between patients with Hashimoto’s 
thyroiditis and a healthy control group, both be-
ing euthyroid [9]. They observed higher levels of 
lymphocytes in comparison to the control group. 
Additionally, Hashimoto’s group presented lower 
level of HGB and higher MPV but with no difference 
in WBC. Next, they confirmed a significantly higher 
neutrophil-lymphocyte ratio (NLR) and platelet-lym-
phocyte ratio (PLR) in Hashimoto’s patients. The 
research of Erikci et al. demonstrated higher MPV 
and PDW in subclinical hypothyroidism compared to 
euthyroidism [10]. The study by Hernik et al. did not 
demonstrate changes in platelet count in hypothyroid 
state [1]. In patients suffering from SAT an increased 
level of platelets and decreased PDW, MPV, and 
P-LCR were observed. Increased platelet count may 
result from a decreased level of megakaryocytes that 
accumulate iron, which leads to increased synthesis 
of poliploidal megakaryocytes. Thrombocytosis may 
also be explained by an inflammatory reaction [7]. 
Kutluturk et al. described the impact of changes 
in the level of thyroid hormones on platelets in 58 
patients with papillary thyroid carcinoma in three 
phases of treatment: preoperative (euthyroidism), 
in hypothyroidism before radioiodine treatment 
(RAI), and subclinical hyperthyroidism after RAI 
(up to 6 months). They did not notice significant dif-
ferences in the level of plates, MPV, NLR, or PLR in 
the hypothyroid phase [11]. 
Hyperthyroidism
Hyperthyroidism may have different aetiology, but 
in countries well supplied with iodine the most com-
mon cause is Graves’ disease. In 1988, Ford and Carter 
noticed a significant impact of thyrotoxicosis on all 
haematopoietic cell lines [12]. In thyrotoxicosis, changes 
(AITDs) [1]. The thyroid hormones stimulate eryth-
ropoiesis through increased expression of the eryth-
ropoietin (EPO) gene and its production in kidneys 
[2]. Previous research confirmed that increased triio-
dothyronine (T3) stimulates a colony of erythrocytes 
in contrast to hypothyroidism that decreases activity 
of erythroid cells in the bone marrow and erythropoi-
esis. In up to 60% of hypothyroid patients, normocytic 
anaemia of different aetiology can be observed, while 
in Hashimoto’s thyroiditis a macrocytic anaemia is 
the most common [1]. It might be explained with 
accompanying Addison-Biermer anaemia associated 
with the presence of autoantibodies against the pari-
etal cells or Castle’s internal factor, which leads to the 
vitamin B12 malabsorption. On the other hand, iron 
deficiency in the course of hypothyroidism further 
exacerbates anaemia by reducing the synthesis of 
thyroid hormones and deteriorating the viability of 
erythrocytes. In microcytic iron deficiency anaemia 
an increase in in the degree of erythrocytes anisocy-
tosis (red cell distribution width, RDW) is observed. 
The exact pathomechanism of iron homeostasis dis-
turbances in patients with Hashimoto’s thyroiditis is 
not well elucidated. Proper L-thyroxine replacement 
therapy normalises haematological parameters [1]. 
Additional iron substitution in subclinical hypothy-
roidism increases the effectiveness of L-thyroxine 
treatment. According to Shakir et al., in patients with 
anaemia the tolerance of L-thyroxine therapy may be 
worse [3]. Therefore, it is advised to initiate treatment 
with iron substitution, then add L-thyroxine. The 
study by Bremner et al. confirmed that even subtle 
changes in thyroid function in euthyroid patients may 
influence the red cell indicators [4]. Hernik et al. ob-
served changes in blood count parameters, especially 
a gradual reduction of RDW in hypothyroid patients 
upon restoration of euthyroid state, which reflects 
improvement of erythropoiesis [1]. In another paper 
an increased RDW was also observed in the course of 
hypothyroidism due to Hashimoto’s thyroiditis [5]. In-
terestingly, Aktas et al. suggested that increased RDW 
may be indicative of Hashimoto’s thyroiditis even in 
euthyroid patients [6]. Additionally, both MCV and 
MCH may be lower in hypothyroidism in comparison 
to euthyroid state [1]. 
Subacute thyroiditis (SAT) is a specific type of 
thyroiditis, which comprises hyper- and hypothyroid 
phases accompanied by essential changes in complete 
blood count.  The following parameters: RDW, HGB, 
HCT, MCV, MCH, and MCHC were found to be lower 
in comparison to healthy subjects [7].
Pregnancy is another state predisposing to 
anaemia. In the 4th week of pregnancy, an increase 
in plasma volume and number of erythrocytes is 
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of complete blood count depend on the cause. The 
mechanism of changes is not fully understood.
In a thyrotoxic state, anaemia concerns 10-34% of 
all patients with cytopaenia [13]. One of the possible 
explanations is that excess thyroid hormones increase 
body metabolism and demand for oxygen [14]. Next, 
hypoxia stimulates the erythropoietin gene expression 
and its synthesis in the kidneys [13]. The erythropoietin 
potentiates erythropoiesis and increases demand for 
iron, folic acid, and vitamin B12. The most likely theory 
is a mixed aetiology of anaemia [2]. In hyperthyroid-
ism, the most common type of anaemia is microcytic 
anaemia, which results from iron deficiency [13, 15]. 
Parameters that enable the diagnosis include increased 
RDW and decreased MCV. Normocytic anaemia may 
occur in Graves’ disease with concomitant bone mar-
row hypoplasia [13]. Macrocytic anaemia occurs due to 
deficiency of folic acid and vitamin B12 [13, 15], whereas 
treatment with antithyroid drugs may induce iatrogenic 
aplastic anaemia [13]. 
The potential link between anaemia and thyroid 
diseases may be hepcidin, which is an important regula-
tor of iron homeostasis. According to Krygier et al., the 
hepcidin concentration decreases during the treatment 
of Graves’ disease [16]. Additionally, they observed 
an improvement in haematological parameters, espe-
cially increase in MCV and MCH. 
Leukopaenia accounts for 15–30% of all cytopaenia 
cases, while neutropaenia concerns 5–18% [13, 17]. The 
pathomechanism is not well recognized. On one hand, 
granulopoiesis is limited by a decreased amount of 
granulocytes in bone marrow. On the other hand, there 
is a hypothetical immunological mechanism linked to 
the identification of antibodies directed against neutro-
phils in patients with thyrotoxicosis [13]. 
Agranulocytosis is often a result of therapy with 
anti-thyroid drugs (ATD). According to Japanese 
researchers, the lower level of granulocytes may oc-
cur in up to 70% patients receiving ATD therapy [18]. 
Therefore, before introduction of ATD, it is crucial 
to evaluate complete blood count and monitor this 
parameter, particularly in the case of fever or throat 
angina [19].
Thrombocytopaenia accounts for 2-5% of all 
cytopaenia cases [13]. Previous studies described 
the occurrence of antibodies against platelets in 
patients with thyrotoxicosis. Bagir et al. estimated 
the significance of MPV to predict the recurrence of 
Graves’ disease; a higher level of MPV was confirmed 
in the group with recurrence of hyperthyroidism in 
comparison to the group of patients in remission 
[20]. The authors explain this phenomenon by an in-
creased metabolic rate due to hyperthyroidism rather 
than an autoimmune reaction. Turan et al. reported 
higher level of platelets in patients with untreated 
Graves’ disease [17]. Franchini et al. underlined the 
correlation between hyperthyroidism and idiopathic 
thrombocytopaenic purpura [17]. Ford et al. observed 
no changes in platelet count in hyperthyroidism. 
They demonstrated a significant decrease in MPV and 
PCT and slight increase in PDW upon euthyroidism 
restoration after the phase of hyperthyroidism [12]. 
Similarly, in the study by Kutluturk et al., MPV, which 
reflects the pace of plates production and activation, 
was significantly elevated in subclinical hyperthyroid-
ism compared to euthyroidism [11].
Previously, pancytopaenia in the course of Graves’ 
disease was described occasionally [13]. Initially, pan-
cytopaenia was linked to deficiency of iron, vitamin 
B12, and coexisting diseases, but in most described 
cases those disturbances were not observed. Pancy-
topaenia is generally chronic and well tolerated [13, 
22]. Pincet and Gorostidi reported no severe anaemia 
complications such as intensive bleeding in the course 
of thrombocytopaenia or infection due to leukopaenia 
[22]. Next, the parameters of complete blood count 
returned to normal range after euthyroidism was 
achieved [13, 14, 23, 24]. For authors the hyperthy-
roidism was an obvious explanation of the previous 
unexplained pancytopaenia [22].
A Polish study on 59 children with de novo di-
agnosed Graves’ disease confirmed the previously 
presented observations. Neutropaenia was noted 
in 37.3% of patients, the decreased level of MCV oc-
curred in 32.2% of children, and 22% of them had 
elevated haemoglobin. The decreased levels of RBC, 
WBC, and PLT were observed in 13.6%, 8.5%, and 
5% of patients, respectively. Higher RDW occurred in 
15.3% of the study group. In most cases, the changes 
in the studied parameters were not significant and 
severe anaemia, neutropaenia, or thrombocytopae-
nia were not found. The studies showed statistically 
significant improvement after ATD therapy. Addition-




Acromegaly is a rare endocrine disorder with two 
to four new cases per million persons per year and 
the incidence of 50-70 cases per million inhabitants 
[26, 27]. The most common cause of acromegaly is 
a growth hormone (GH)-secreting pituitary adenoma 
[28]. Changes in the blood count commonly accom-
pany acromegaly [29]. Regular observation of basic 
blood parameters may be of value considering the 
high morbidity and mortality due to cardiovascular 
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Valerio et al. investigated the effect of rhGH treat-
ment on erythropoiesis by assessing RBC, HGB, HCT, 
and MCV in 19 children with isolated GH deficiency 
(12 cases) and multiple pituitary hormone deficiency 
(MPHD; 7 cases). During rhGH treatment HGB, HCT, 
and RBC increased, which indicates the erythropoietic 
effects of GH in vivo. The authors hypothesised that the 
deterioration of red cell parameters in hypopituitarism 
is mainly attributable to GH deficiency. Balancing 
the other pituitary axes does not fully restore normal 
erythropoiesis until the GH deficiency has been cor-
rected [42].
In adults a prolonged administration of rhGH 
also increased HGB [43]. Haemoglobin concentration 
peaked at week 120 of the treatment, with mean in-
crease of 0.73 ± 0.2 mmol/L. The fold of increase was 
higher in men. HGB concentration changes correlated 
with IGF-1. The maximum concentration of HGB was 
observed in the majority of patients with IGF-1 values 
close to the normal range. Leukocyte and platelet counts 
remained unchanged throughout the treatment.
Anaemia is a common feature of hypopituitarism. 
Nishioka and Haraoka investigated the influence of hy-
drocortisone and/or levothyroxine replacement therapy 
on HGB concentration in patients with hypopituitarism 
[44]. HGB concentrations were significantly lower in 
patients with hypopituitarism in the corticoid, thyroid, 
somatotropic, and gonadotropic axes compared with 
healthy controls. The HGB concentration decreased 
with the disease duration. In some patients, hydrocor-
tisone and levothyroxine supplementation improved 
HGB concentrations; however, it was not sufficient in 
all. These results confirm previous observations that 
additional rhGH and/or androgen replacement therapy 
is necessary to obtain further improvement. 
Additionally, the study focused on the morphotic 
elements of blood. The RBC, HCT, and platelets were 
significantly lower in patients with hypopituitarism 
compared to the control group. No differences in WBC 
or reticulocytes were observed.
Beshyah et al. demonstrated that haemostasis 
in adult patients treated for hypopituitarism is not 
disturbed [45]. Twenty-one patients with hypopituita-
rism, treated with thyroxine, hydrocortisone, and sex 
hormones, participated in the study. All subjects were 
GH-deficient and had decreased IGF-1 concentrations 
compared to the control group. Blood count parameters 
including HGB, WBC, PLT, and HCT did not differ 
significantly between groups.
Cushing’s disease
ACTH (adrenocorticotropic hormone)-secreting pi-
tuitary adenomas are the most common underlying 
condition of endogenous hypercortisolaemia [46, 47]. 
diseases in this group of patients [30]. Current stud-
ies have demonstrated alterations in RDW, MCV, and 
MPV in acromegaly. Uçler et al. compared RDW be-
tween patients with active and inactive disease treated 
either only surgically or with adjuvant somatostatin 
analogues (SSA) [31]. RDW was significantly higher 
among patients with inactive acromegaly receiving 
SSA following surgery. For surgical treatment alone, 
the results did not reach significance. Strauch et al. 
observed increased MCV values in male patients with 
active acromegaly compared to female patients and 
healthy controls [32]. MCV correlated positively with 
the GH concentration, suggesting that excessive en-
dogenous GH secretion is responsible for a reversible 
increase in MCV in acromegaly.
MPV has aroused interest as a useful indicator of 
cardiovascular risk [33]. Research on MPV in acro-
megaly is inconclusive. Several studies have shown 
an increased MPV in acromegaly compared to healthy 
individuals [34–36], while another demonstrated no 
significant differences [37, 38]. Surgical treatment 
with concomitant use of SSA was found to either in-
crease or decrease MPV, whereas in patients treated 
only surgically no changes of MPV were noted [31, 
37]. The treatment with SSA may thus increase MPV 
and be associated with greater risk of cardiovascular 
diseases. Demirpence et al. demonstrated a significant 
decrease in MPV following surgery without adjuvant 
therapy [35]. MPV values remained unchanged in the 
active phase of the disease and in patients in remission 
who received SSA after surgery. These results suggest 
that, although acromegaly is pharmacologically con-
trolled with SSAs, the risk of cardiovascular diseases 
may remain elevated.
Cardiovascular diseases are associated with chronic 
inflammation. The ratios of neutrophils to leukocytes 
and platelets to leukocytes are good indicators of in-
flammation [39]. Üçler et al. demonstrated a positive 
correlation between the ratio of neutrophils to lym-
phocytes and insulin-like growth factor 1 (IGF-1), as 
well as between the ratio of platelets to lymphocytes 
and IGF-1 [40]. The authors concluded that an inflam-
matory state due to uncontrolled IGF-1 secretion may 
increase the risk of mortality and morbidity in the 
course of acromegaly.
Hypopituitarism
Hypopituitarism comprises a group of symptoms 
related to the deficiency of one or more pituitary hor-
mones. Most commonly it results from damage to the 
pituitary or hypothalamus due to the sellar lesions, 
autoimmune diseases, or iatrogenic injuries. Less fre-
quently, it is caused by congenital or developmental 
defects [41].
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Numerous blood count abnormalities are associated 
with Cushing’s syndrome, including an increased or 
decreased RBC and haemoglobin, as well as elevated 
WBC and PLT.
Possible explanations of erythrocytosis and elevated 
haemoglobin include decreased erythrophagocytosis 
caused by glucocorticoid (GCS) excess and stimula-
tion of erythropoietin synthesis or positive regulation 
of erythropoiesis (e.g. participation in stress eryth-
ropoiesis or blood-loss associated erythropoiesis). 
Erythrocytosis may be reflected as a typical Cushing’s 
syndrome appearance, namely a red, moon-shaped 
face [48]. Fluctuations in testosterone concentration in 
hypercortisolism may also affect blood count. Patients 
suffering from Cushing’s syndrome due to GCS ex-
cess are likely to have decreased LH and testosterone 
concentrations. Because testosterone stimulates RBC 
proliferation (influence stronger than GCS), the blood 
count may show decreased HCT, RBC, and HGB [48, 49]. 
Polycythaemia observed in Cushing’s disease occurs 
more frequently among women due to the less impor-
tant role of testosterone in the erythropoiesis regulation. 
As Cushing’s disease occurs predominantly in women, 
polycythaemia is considered a typical symptom [48].
Another blood count abnormality reported in hy-
percortisolism is a considerable or slight increase in 
WBC. Most commonly we observe neutrophilia with 
eosinophils and lymphocytes below or in lower normal 
range [48]. The mechanisms responsible for leukocytosis 
include prolonged half-life and postponed neutrophil 
apoptosis, decreased migration to tissues, and increased 
inflow of granulocytes into the bloodstream induced 
by stress factors such as cortisol or catecholamines [50].
Platelet concentration is either normal or increased 
[50]. An increased risk of venous thrombo-embolic 
disease must be considered [51].
Hyperprolactinaemia
The largest proportion of pituitary adenomas are 
prolactinomas. They are considered the main cause 
of hyperprolactinaemia, which is the most common 
hormonal abnormality among the hypothalamic and 
pituitary disorders [52, 53].
The most frequent blood count abnormality ob-
served in hyperprolactinaemia is thrombocytosis [54], 
although the research on this topic is limited. The 
change of platelet parameters is not observed in the 
pregnancy-induced hyperprolactinaemia [54]. On the 
other hand, changes in haemostasis parameters are 
observed more frequently and include, e.g., increased 
platelet activation and an increased fibrinogen con-
centration, which, taken together, contribute to the 
increased risk of thrombosis, atherosclerosis, and 
heart disease [55, 21]. This also applies to patients with 
macroprolactinaemia [55]. Hyperprolactinaemia does 




In Addison’s disease (primary adrenal insufficiency), 
the most common abnormality regarding blood count 
parameters is eosinophilia. Eosinophilia in Addison’s 
disease was described in early works from the 1970s 
[57]. Eosinophil concentration above 500/mm3 was 
found in 4 out of 26 subjects. In one 21-year-old patient 
the concentration reached 800/mm3 in the absence of 
any parasitic infection. Oral administration of cortisol 
reduced eosinophilia in this patient, while daily use 
reduced the myeloid production of eosinophils and 
restored eosinophil concentration. Eosinophilia has also 
been described in a patient with adrenal insufficiency 
due to tuberculosis [58]. However, it cannot be clearly 
stated that eosinophilia is caused solely by low plasma 
cortisol levels, because it is not present in all patients 
with Addison’s disease.
In patients with adrenal insufficiency, treatment 
with dehydroepiandrostenedione sulphate (DHEA-
S) has an immunomodulatory effect, increasing the 
number of T cells by stimulating their proliferation. 
A 12-week exposure of cultured lymphocytes to DHEA-
S increased their number by more than 10 times while 
reducing the number of NK cells by 37–43%. Addition-
ally, in one trial, the treatment increased the number of 
B cells and monocytes [59]. However, an experimental 
study in mice showed that long-term use of DHEA-S 
in these animals did not affect the T-cell subpopula-
tion or the production of antibodies after erythrocyte 
immunization [60].
Addison’s disease may coexist with other autoim-
mune disorders as a part of the autoimmune polyglan-
dular syndrome [61]. Then it may be accompanied by 
pernicious anaemia — a macrocytic anaemia due to 
vitamin B12 deficiency.
Pheochromocytoma and hyperaldosteronism
Blood count changes are also reported in pheochromo-
cytoma - a tumour originating from the adrenal me-
dulla. Experimental studies have shown that high-dose 
catecholamine administration increases WBC and PLT, 
and promotes platelet activation, which is also observed 
in chronic stress [62, 63]. Neutrophilia was reported in 
a patient with phaeochromocytoma and non-cardiac 
pulmonary oedema [64]. The authors hypothesised 
that elevated WBC may lead to respiratory failure by 
increasing the permeability of pulmonary vessels and 
promoting the development of that complication [64].
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Zelink et al. compared blood count parameters 
between patients with pheochromocytoma, primary 
hyperaldosteronism, and idiopathic arterial hyperten-
sion [65]. WBC in pheochromocytoma was significantly 
higher compared to the group of patients with primary 
aldosteronism or the control group. On the other hand, 
the number of platelets was higher in patients with 
phaeochromocytoma compared to primary hyperaldo-
steronism, but lower than in the control group. There 
were no significant differences in RBC and HGB  among 
the studied subgroups. After surgical treatment and 
normalization of catecholamine concentrations, WBC, 
neutrophils, and platelets decreased. The influence of 
catecholamines on the blood morphotic elements is 
explained by their direct interaction with cell surface 
receptors: PLT — alpha receptors stimulated by epi-
nephrine, and WBC — adrenoreceptors.
An elevated HGB concentration has also been 
described in a 20-year-old patient with late diagnosis 
of Bartter ’s syndrome type IV. Other morphological 
parameters (leukocytes, platelets), as well as plasma 
iron, transferrin, and erythropoietin concentration were 
within the normal ranges [66]. The reasons for this phe-
nomenon remain unclear. A similar clinical situation, 
described by Erkelens many years ago, was interpreted 
by the author with the hypertrophy of the glomerular 
apparatus, which led to the overproduction of renin 
and an increase in the synthesis of erythropoietin [67]. 
It is now known that the glomerular apparatus is not 
the main site of erythropoietin synthesis, the concen-
tration of which in the described case was within the 
normal range. The occurrence of erythrocytosis may 
be the result of polyuria, which, however, also did not 
apply to this patient.
Premature adrenarche
Adrenarche is the process of adolescence in which the 
child’s adrenal cortex begins secreting androgen pre-
cursors. These mainly include dehydroepiandrosterone 
and androstenedione. This phenomenon is considered 
premature when it occurs before the age of 8 years in 
girls and before the age of 9 years in boys. Adrenal hor-
mones promote secondary sex characteristics such as 
the appearance of pubic and underarm hair, acne, and 
sweat with a characteristic smell. When accompanied 
by gonadarche, it is classified as premature puberty. Ad-
renarche praecox (AP) is more common in girls — 9/10 
patients [68]. Reports indicate a relationship between 
AP and altered values of blood count parameters in 
patients compared to the group of healthy people. It 
has been shown that the RBC level is higher in girls 
with AP than in the same sex in the control group. Such 
a relationship did not occur in the group of boys. At the 
same time, the remaining blood count parameters did 
not differ significantly between the affected and healthy 
subjects of both sexes [68].
Disorders of the secretory function  
of the gonads
Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is an endocrine-met-
abolic disorder that affects 5 to 25% of women in 
reproductive age [69–72]. Characteristic features for 
this disease include oligo- or anovulation, polycystic 
ovaries on ultrasound imaging, and clinical and bio-
chemical hyperandrogenism. PCOS is also associated 
with metabolic disorders such as glucose intolerance, 
insulin resistance, and obesity. In patients with PCOS, 
an increase in many markers of inflammation is also 
observed [72]. Chronic inflammation is a significant 
risk factor for the development of atherosclerosis and 
cardiovascular diseases.
WBC is an indicator of inflammation and is rou-
tinely measured in the blood count. In PCOS patients 
a significantly higher WBC was observed compared 
to healthy women, matched for age and BMI. In-
creased concentration of leukocytes is an independent 
predictor of inflammation and atherosclerosis [72]. 
Research indicates a correlation between WBC, CRP, 
insulin resistance, BMI, and visceral fat. However, it 
is still not fully understood whether inflammation 
is directly related to PCOS or reflects the insulin 
resistance and obesity associated with the syndrome 
[72]. Other morphological parameters considered as 
inflammation indicators include PLT, MPV, PDW, and 
PCT. Cardiovascular, cerebrovascular, and inflamma-
tory diseases influence PLT counts. MPV, PLR and 
NLR indices have also been considered as markers 
of inflammation. However, studies in PCOS patients 
demonstrated no changes in the above-mentioned 
blood count parameters, and thus they are not ap-
plicable in this syndrome [72]. Due to the limited 
research in this field, further studies are necessary to 
confirm those findings. Metformin therapy in PCOS 
reduces WBC (including lymphocyte and monocyte 
count) and thereby reduces inflammation and the risk 
of atherosclerosis and cardiovascular diseases [69].
Male hypogonadism
Male hypogonadism results in gonadal dysfunction. 
Due to its aetiology, hypogonadism is classified as:
 — hypergonadotropic (primary) hypogonadism, in 
which the testes are unable to perform an endo-
crine or reproductive function due to damage to 
their structure. This group includes among others: 
gonadal dysgenesis, congenital lack of testes, Kline-
felter syndrome;
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 — hypogonadotropic (secondary) hypogonadism, 
resulting from hypothalamic-pituitary insufficiency 
and decreased gonadotrophins. It occurs in the 
course of hyperprolactinaemia, Kallmann’s syn-
drome, hypopituitarism, isolated FSH deficiency or 
might be idiopathic;
 — mixed hypogonadism — late-onset hypogonadism 
(LOH)
 — syndromes associated with the target tissue resis-
tance to sex hormones — aromatase deficiency, 
androgen insensitivity syndrome [73].
Clinical presentation of male hypogonadism re-
sults from testosterone deficiency. Erythropoiesis is 
an androgen-dependent process. Therefore, a mild 
anaemia is common in hypogonadal patients. Substi-
tution of testosterone restores proper erythropoiesis 
and might induce polycythaemia in up to 25% of 
patients [73–76]. Blood count is one of the basic tests 
allowing indirect assessment of the effectiveness of 
the treatment of hypogonadism. Regular blood count 
monitoring, with particular attention paid to HCT, is 
recommended during testosterone therapy [73, 74, 
76]. If HCT increases above 54%, the dose should be 
reduced or the intramuscular drug administration 
route changed to transdermal [74]. In some cases, 
a phlebotomy is recommended. If the aforementioned 
actions are unsuccessful in decreasing HCT, testoster-
one therapy should be discontinued and restarted after 
normalization of this parameter.
In idiopathic hypogonadotropic hypogonadism 
(IHH) HGB, HCT, and MCV were reported to decrease 
compared to the healthy individuals. Conversely, 
RDW in patients with IHH was higher than in healthy 
people, which reflects a greater anisocytosis of red blood 
cells. In IHH PLT increased significantly compared to 
the control group. The study cited above concerned 
newly diagnosed, untreated IHH patients, thus changes 
in the erythropoiesis are a direct consequence of this 
disease [75]. 
Doping 
Doping involves the use of methods aimed at increasing 
the physical performance of athletes, which at the same 
time go beyond the limits of conventional training. Due 
to gradual blurring of boundaries between “proper” 
training and doping, the latter can be considered as 
methods that require medical intervention.
According to the 2015 World Anti-Doping Agency 
(WADA) definition, doping is a breach of at least one 
of the anti-doping rules included in the Anti-Doping 
Code. These include: the presence of a Prohibited Sub-
stance, its metabolites or markers in a sample collected 
from an Athlete, use / attempted use by an Athlete of 
a prohibited substance or method, and evasion or re-
fusal to collect samples for doping testing. The code also 
lists the following: possession of prohibited substances, 
trade or attempted trade in such substances, as well 
as administering or attempting to administer them to 
an athlete [77].
In order to detect doping and disqualify athletes 
using illegal methods, WADA has developed the Ath-
lete Biological Passport (ABP). It includes, inter alia, 
haematological parameters. Peripheral blood counts 
include parameters listed in the haematological ABP: 
HCT, HGB, MCH, MCV, MCHC, PLT, RBC, WBC, and 
RET [63]. In view of the above, an endocrinologist can 
assess certain abnormalities characteristic for doping 
on the basis of morphology.
Androgenic anabolic steroids (AAS) are a widely 
used method of doping, both in professional athletes 
and amateurs, being synthetic testosterone deriva-
tives. They are mainly applied to increase the muscle 
mass; therefore, their use is often associated with sports 
that require significant muscle strength in a short time, 
e.g. weight lifting or sprinting. Smaller doses of anabolic 
steroids are taken by cyclists to increase the erythrocyte 
count and haematocrit, which increases the supply of 
oxygen to the cells [78].
Chrostowski et al. investigated the effect of 
high-dose ASS administration on the renin-angioten-
sin-aldosterone axis. Forty bodybuilders were enrolled 
and divided into ASS-urine positive and negative 
groups. In individuals using AAS, significantly higher 
levels of RBC, HGB, and HCT were reported compared 
to the group not taking ASS [79]. These results confirm 
both the effectiveness of AAS as a doping agent and 
their influence on blood count parameters. Properly 
performed differential diagnosis should include doping 
as one of the potential causes of abnormally high blood 
count parameters.
Conclusions
In the course of thyroid dysfunction and AITD, the 
worsening of RBC parameters is observed, which im-
prove following successful therapy. Agranulocytosis 
may be one of side effects of ATD used for hyperthy-
roidism therapy. The most common form of anaemia in 
the case of thyroid dysfunction is normocytic anaemia. 
Macrocytic anaemia is more typical of hypothyroidism, 
while microcytic is more typical for hyperthyroidism. 
Unexplained anaemia or an increase in RDW should 
prompt the diagnostics directed towards thyroid dis-
eases. In the course of Cushing’s disease an increase in 
PLT and WBC is observed. The most common is neu-
trophilia, while the concentration of eosinophils and 
lymphocytes may be in the lower reference ranges. In 
hypercortisolism, both anaemia and hyperaemia may 
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occur. In hypopituitarism, a decrease in RBC, HGB, 
HCT, and PLT is observed. In patients with acromegaly, 
an increase in the MCV parameter is detected. Tes-
tosterone deficiency is accompanied by a decrease in 
RBC parameters, while androgen excess may induce 
polycythaemia. Routine control of blood count is rec-
ommended during the therapy with testosterone. In 
women with PCOS features of chronic inflammatory 
state are detected, which may be reflected by an in-
crease in WBC. Evaluation of complete blood count is 
a useful tool in the basic diagnostics and monitoring of 
endocrine disorders.
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